Release issued 12th December 2005

Paris, France : - Ethypharm announced today changes in its Board of Directors and in the organisation of the company.

Further to the leading DDS Company Management restructuration, Patrice Debregeas, former President and CEO has been dismissed by the shareholders Assembly on November, 10th 2005.

Gérard Leduc, former COO, has been appointed by the Board of Directors as President and CEO, Henry Martin as vice CEO and Pascal Oury as Head Pharmacist.

New Directors include Henry Martin, Sébastien Rozès (ABN AMRO) and Bertrand Hieaux (former banker).

The Company now will benefit from a united and cohesive general management team to increase its worldwide presence and expertise.

About Ethypharm www.ethypharm.com Ethypharm is a pharmaceutical laboratory specialized in controlled release systems of medical products for the oral route. Its principal therapeutical areas concern pain, cardio-vascular and the central nervous system. The Company has more than 50 products launched by business partners of international repute in approximately 70 countries. Ethypharm develops and manufactures its products in compliance with the current pharmaceutical norms worldwide. The Company has developed a large range of technology platforms for the administration of products by the oral route, including controlled release, orally disintegrating taste-masked formulations, and systems for the improvement of the solubility of active substances of low solubility. Ethypharm is present on the principal world health markets with plants and Research & Development centres in Europe, in the United States of America and in Asia. The Laboratory has a total of 600 salaried employees worldwide.

---------------------------------------------

Contacts Presse

Ethypharm Caroline Guinet, Corporate Communications Tel: +33 (0)1 41 12 17 20

(13th July 2007) Buprenorphine - Merck Generiques becomes the 2nd partner of Ethypharm in France

(10th April 2007) Astorg Partners leads MBO of Ethypharm alongside management and existing investors

(14th October 2004) FIRST APPROVAL OF ETHYPHARM'S ONCE-A-DAY MORPHINE SULFATE FORMULATION IN DENMARK

(30th September 2004) ETHYPHARM's formulation of Tramadol SR Bid approved in Germany

(8th June 2004) Ethypharm and Kowa enter into Licence and Supply Agreement for two OroDispersibleTablets in Japan. The Two Companies to Develop an Oral Flashtab® Version of Paracetamol and Ibuprofen for Japan.